Structure-based drug screening has identified the FDA-approved drug Tegaserod as a potential YTHDF1 inhibitor, which blocks its interaction with m6A-modified RNA, suppresses CCNE2 translation, reduces AML cell viability, and prolongs survival in patient-derived xenograft models (40). The gene discussed is YTHDF1; the disease is acute myeloid leukemia.